Posted on 05/14/2021 10:00:17 AM PDT by SeekAndFind
Recently, a randomized controlled trial led out of the Rehman Medical College in Peshawar, Pakistan had some limitations and will probably be ignored by most of the main regulatory bodies. Nonetheless, the study offers some interesting data for investigating how to save lives during the pandemic. The researchers investigated Azithromycin versus Azithromycin and Ivermectin in 100 mild COVID-19 patients. Randomized 1:1, the investigators and study team measured symptom resolution. Both of the study groups also received tablets of paracetamol (Acetaminophen) at 500 mg if needed, Vitamin C at 500 mg once a day for 15 days, Zinc at 20 mg twice per day for 15 days, and Vitamin D as a supplemental injection (PO 200,000 units once). Interestingly, in regards to vitamin D, some studies reveal efficacy if administered in the form of calcifediol intravenously. The form of vitamin D isn’t declared but if administered via IV, it may be calcifediol (oral vitamin D takes at least a week for the liver to convert into Calcifediol). TrialSite contributors suggest that the vitamin D dosage may have been too low, and Tylenol trumps aspirin. The results seem impressive, however, and should be better understood by public health authorities interested in this approach to reduce hospitalization and death rates, particularly in economically challenged, low-and middle-income countries (LMICs). The study team found that the use of azithromycin and ivermectin was more effective than just administering azithromycin alone for mild COVID-19 patients. Both groups received supplements.
A valued TrialSite contributor from Southern California reports that the study was limited on the details outside of their measured outcomes. It’s understood now that negative outcomes occur once the disease transitions into what’s considered a pulmonary phase at about Day 8 mark of the infection lifecycle. Consequently, a goal of these studies is to reduce the actual number of participants that fail to recover during the early stages of the illness.
From this vantage, the goal of such a study is to reduce the number of subjects that progress to Day 8, and the study results raise an interesting and important discussion. That is, upon review of the actual number of patients that progressed past 8 days, the results are significant. Noteworthy, all of the patients in both groups were RT-PCR negative by 21 days, and this could indicate that the supplements helped the control group—but of course, that’s not fully certain. TrialSite suggests a review for those readers that are interested in studies in LMICs utilizing low-cost generic combination therapy with supplements yielding highly efficacious results.
Part of the Rehman Medical Institute, Rehman Medical College is a premier medical college in Khyber Pakhtunkhwa, Pakistan.
R. Rizwan Faisal, MBBS, M.Phil, PhD, Department of Pharmacology, Rehman Medical College, Peshawar, Pakistan
Call to Action: Follow the link to read the study.
Ping for your interest
I’m on it prophylactically, along with HCQ. Cheap and harmless insurance.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.